Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9728612 | 0.77 | MAPT (0.79) | MAPTMAPK1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL11528732 | 0.73 | KMT2A (0.52) | MAPTMAPK1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL6712646 | 0.73 | L3MBTL1 (0.52) | MAPTMAPK1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL8353349 | 0.73 | MEN1 (1.00) | MAPTMAPK1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL243259 | 0.73 | MEN1 (1.00) | MAPTMAPK1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL11514191 | 0.73 | MAPT (0.51) | MAPTMAPK1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL15000805 | 0.72 | MAPT (0.71) | MAPTMAPK1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL19041388 | 0.71 | MAPT (0.69) | MAPTMAPK1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL19041463 | 0.71 | MAPT (0.69) | MAPTMAPK1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3155441 | 0.70 | NFE2L2 (0.50) | KMT2AMEN1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192748-A1 | Heterocyclic compounds | BOEHRINGER INGELHEIM PARMACEUTICALS, INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192748-A1 | Heterocyclic compounds | IL1B, CCL5, IL4 | MAPT 3685/4885MAPK1 721/4885KMT2A 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.